Fused in sarcoma (FUS) forms phase-separated droplets that mediate its interaction with the Pol II CTD [110–112], and PRMT5-catalyzed symmetric dimethylation of FUS is required for its stable association with Pol II (Fig. 2F) [113]. This evidence concerns the gene FUS and sarcoma.